Nifty 17941.35 (-0.95%)
Sensex 60070.57 (-1.13%)
Nifty Bank 38042.3 (-0.44%)
Nifty IT 37300.4 (-2.08%)
Nifty Financial Services 18275.25 (-1.05%)
Adani Ports 744.00 (-2.48%)
Asian Paints 3284.00 (-2.66%)
Axis Bank 729.45 (0.59%)
B P C L 394.00 (-1.03%)
Bajaj Auto 3455.00 (1.59%)
Bajaj Finance 7574.80 (-2.18%)
Bajaj Finserv 18074.85 (-0.43%)
Bharti Airtel 705.00 (-1.31%)
Britannia Inds. 3579.40 (-1.17%)
Cipla 896.20 (-0.66%)
Coal India 164.00 (1.99%)
Divis Lab. 4471.35 (-1.23%)
Dr Reddys Labs 4690.00 (-0.08%)
Eicher Motors 2720.35 (-0.58%)
Grasim Inds 1811.15 (-2.22%)
H D F C 2619.35 (-1.62%)
HCL Technologies 1200.50 (-1.58%)
HDFC Bank 1517.65 (-0.76%)
HDFC Life Insur. 656.45 (-1.89%)
Hero Motocorp 2699.70 (0.25%)
Hind. Unilever 2309.85 (-2.52%)
Hindalco Inds. 504.75 (1.76%)
I O C L 125.40 (1.17%)
ICICI Bank 810.80 (-1.49%)
IndusInd Bank 891.10 (-0.95%)
Infosys 1864.95 (-2.91%)
ITC 220.50 (-0.11%)
JSW Steel 674.70 (-0.81%)
Kotak Mah. Bank 1905.70 (-1.88%)
Larsen & Toubro 2020.30 (-0.09%)
M & M 895.40 (0.36%)
Maruti Suzuki 8050.00 (1.70%)
Nestle India 18921.60 (-2.36%)
NTPC 134.90 (-0.07%)
O N G C 170.45 (4.03%)
Power Grid Corpn 205.05 (-0.05%)
Reliance Industr 2520.60 (-0.05%)
SBI Life Insuran 1249.00 (-1.34%)
Shree Cement 26396.00 (-2.80%)
St Bk of India 514.80 (1.58%)
Sun Pharma.Inds. 838.10 (-1.02%)
Tata Consumer 717.50 (-1.91%)
Tata Motors 521.10 (2.02%)
Tata Steel 1207.55 (1.06%)
TCS 3915.95 (-1.87%)
Tech Mahindra 1670.25 (0.57%)
Titan Company 2593.20 (-0.28%)
UltraTech Cem. 7426.00 (-1.72%)
UPL 812.45 (1.67%)
Wipro 621.20 (-1.91%)
IPCALAB

Ipca Laboratories Ltd.

₹1075.05

Investment Ratings

  • Master Rating:
  • Ipca Laboratories has an operating revenue of Rs. 5,634.71 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 26% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 9 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has great fundamentals and relative strength but it needs to see some buyer interest to stay in momentum.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Recommendation HoldBuy Sell

Result Highlights

Ipca Laboratories Ltd Synopsis

NSE-Medical-Generic Drugs

Ipca Laboratorie is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 5139.16 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2021. Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837.
  • Market Cap

    INR 27,284.59 Cr

  • Sales

    INR 5,258.58 Cr

  • Shares in Float

    13.70 Cr

  • No of Funds

    288 K

  • Yield

    0.76%

  • Book Value

    5.6

  • U/D Vol Ratio

    0.4

  • LTDebt/Equity

    2%

  • Alpha

    -0.03

  • Beta

    0.34

Ipca Laboratories Ltd Ownership
Ipca Laboratories Ltd Management

Ipca Laboratories Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eps And Sales Estimates

Ipca Laboratories Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 4,752.723,677.543,136.662,694.952,475.12
Fixed Assets Annual Cr 2,050.601,925.161,806.061,927.842,040.84
Total Non Current Assets Annual Cr 2,732.342,472.462,171.992,200.542,256.30
Total Current Assets Annual Cr 3,277.772,712.112,285.551,907.171,711.65
Total Assets Annual Cr 6,010.115,184.574,457.544,107.713,967.95
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 374.67291.06248.25213.55196.13
ROE Annual % 24.0017.7414.508.647.60
ROCE Annual % 28.0720.3016.729.849.31
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 30.6622.4220.5815.0614.58

Ipca Laboratories Ltd Technicals

EMA & SMA

CURRENT PRICE

1075.05 (2.5)

    • Bullish Moving Averages 11
    • Bearish Moving Averages 5

EMA

  • 20 Day

    1055.87

  • 50 Day

    1061.09

  • 100 Day

    1077.56

  • 200 Day

    1091.36

Ipca Laboratories Ltd Resistance and support

1055.42 PIVOT

  • First Resistance

    1065.84

  • Second Resistance

    1082.82

  • Third Resistance

    1093.24

  • First Support

    1038.44

  • Second Support

    1028.02

  • Third Support

    1011.04

  • RSI

    48.21

  • MFI

    44.32

  • MACD

    5.33

  • MACD signal line

    6.87

Ipca Laboratories Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 332,396 17,420,874 52.41%
Week 327,800 17,501,242 53.39%
1 Month 362,814 16,069,042 44.29%
6 Month 451,657 22,781,592 50.44%

Ipca Laboratories Ltd Price change analysis

78.87

Over 1 month

Low High
962.52 1128.5

-132.75

Over 3 month

Low High
962.52 1225.42

26.23

Over 6 months

Low High
962.52 1383.55

8.85

Over Year

Low High
892.7 1383.55

Corporate Action

Date Purpose Remarks
2021-11-13 Qtr Results, Int. Dividend & Stock Split
2021-08-05 Quarterly Results
2021-05-28 Audited Results
2021-02-04 Quarterly Results
2020-11-07 Quarterly Results & Interim Dividend
Date Purpose Remarks
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
2020-11-17 INTERIM Rs.8.00 per share(400%)Interim Dividend
2020-02-20 INTERIM Rs.5.00 per share(250%)Interim Dividend
Date Purpose Remarks
2022-01-11 Split Rs. split from Rs. 2/- to Re. 1/-.

MF Shareholding

Similar Stocks

News

Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: P

Net Sales are expected to decrease by 2.2 percent Y-o-Y (down 10.8 percent Q-o-Q) to Rs 1,378.3 crore, according to Prabhudas Lilladher. Read More

IPCA LABORATORIES LTD. - 524494 - Compliances-Reg. 39 (3) -

Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 20 Read More

Ipca Labs down 6% as stock turns ex-date for 1:1 split

The pharmaceutical company has fixed Tuesday, January 11, 2022, as the 'record date' for the members entitlement of sub-divided shares. Read More

IPCA LABORATORIES LTD. - 524494 - Compliances-Certificate un

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021 Read More

IPCA LABORATORIES LTD. - 524494 - Statement Of Investor Comp

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor compl Read More

FAQs

Stock Directory-

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All 0-9